ArticleHepatobiliary surgery and nutrition2022

Pan-peroxisome proliferator-activated receptor agonist lanifibranor as a dominant candidate pharmacological therapy for nonalcoholic fatty liver disease.

Masato Yoneda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.